HLB Therapeutics Co.,Ltd.
115450
Kedudukan dalam Saham
#18346
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Harga Saham
$2.07
Modal Pasaran
$194.92M
Perubahan (1 hari)
10.37%
Perubahan (1 tahun)
1.05%
Negara
KR
Perdagangan HLB Therapeutics Co.,Ltd. (115450)
Kategori
Healthcare
Bilangan saham terbitan bagi HLB Therapeutics Co.,Ltd. (115450)
Bilangan saham terbitan setakat October 2026: 0
Menurut laporan kewangan terkini dan harga saham HLB Therapeutics Co.,Ltd., bilangan saham terbitan semasa ialah 0. Pada akhir October 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk HLB Therapeutics Co.,Ltd. (115450) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| - | - |
CH
|
